相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation
Dirk Kuck et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer
Alfonso Duenas-Gonzalez et al.
DRUGS (2010)
Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression
Yinhong Song et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1
Narender Singh et al.
CHEMMEDCHEM (2009)
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
Jianqing Lin et al.
CLINICAL CANCER RESEARCH (2009)
Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
David J. Stewart et al.
CLINICAL CANCER RESEARCH (2009)
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
Maria Teresa Voso et al.
CLINICAL CANCER RESEARCH (2009)
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Adi I. Daud et al.
CLINICAL CANCER RESEARCH (2009)
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Pamela Munster et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Association between CpG Island Methylation of the WWOX Gene and Its Expression in Breast Cancers
X. Wang et al.
TUMOR BIOLOGY (2009)
Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors
Alfonso Duenas-Gonzalez et al.
CANCER TREATMENT REVIEWS (2008)
Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
Fadi Braiteh et al.
CLINICAL CANCER RESEARCH (2008)
Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells
Alice Y. S. Law et al.
EXPERIMENTAL CELL RESEARCH (2008)
Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice
G. Howard et al.
ONCOGENE (2008)
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
Kim Appleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
M. Candelaria et al.
ANNALS OF ONCOLOGY (2007)
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study
Erick de la Cruz-Hernandez et al.
VIROLOGY JOURNAL (2007)
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
Maria de Lourdes Mora-Garcia et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
Claudia Arce et al.
PLOS ONE (2006)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma
Jared A. Gollob et al.
CLINICAL CANCER RESEARCH (2006)
Hydralazine target:: From blood vessels to the epigenome
C Arce et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
G Bug et al.
CANCER (2005)
Epigenetics of cervical cancer. An overview and therapeutic perspectives
Alfonso Duenas-Gonzalez et al.
MOLECULAR CANCER (2005)
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A gynecologic oncology group study
HJ Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
Alma Chavez-Blanco et al.
MOLECULAR CANCER (2005)
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes -: art. no. 44
P Zambrano et al.
BMC CANCER (2005)
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
OH Krämer et al.
EMBO JOURNAL (2003)
Induction of tumors in mice by genomic hypomethylation
F Gaudet et al.
SCIENCE (2003)
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
CJ Phiel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
